Please assess the completion status of the following clinical trial:

Trial Title: Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients confirmed Hodgkin's lymphoma at refractory at first line therapy, relapse early or late;~* Age \> 18 years;~* Life expectancy \> 3 months;~* Cardiac, pulmonary, renal and liver functions with normal range;~* Written informed consent.~Exclusion Criteria:~* Any psychological, familiar or geographical conditions that could potentially hinder the compliance to the protocol;~* renal failure as creatinine\> 1.2 mg/dl or creatinine clearance \<60 ml/min;~* AST/ALT or bilirubin\> 2.5 times the norm;~* HCV positivity with signs of ongoing viral replication (HCV PCR + AST\>1.5-2x normal);~* Heart disease clinically significant: eg. severe hypertension not controlled, multifocal uncontrolled cardiac arrhythmias, symptomatic ischemic heart disease or congestive heart failure class NYHA class III-IV (Annex 2), previous acute myocardial infarction;~* Ventricular ejection fraction \<45%;~* decompensated diabetes mellitus not controlled by insulin therapy; Disease with significant pulmonary function defined as FEV1 \<65% of predicted or DLCO \<50% of predicted value;~* HIV positive patients;~* Patients with uncontrolled infection;~* Neoplasia in the last 3 years except carcinoma in situ uterus, neck and basal skin cancer or prostate cancer in early stage localized exeresi treated with surgery or brachytherapy with curative intent, a good prognosis DCIS breast treated with surgery alone;~* Drug addiction or alcoholism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).